Uncategorized
Share this news article...
Share on LinkedIn
Linkedin
Share on Facebook
Facebook
Tweet about this on Twitter
Twitter
Share on Google+
Google+
Email this to someone
email

FSD Pharma Announces Positive ISA Report for “Steady Stomach” CBD Combination

 

 

 

 

 

FSD Pharma Inc. (CSE: HUGE) (OTCQB: FSDDF) (FRA: 0K9) announced today that its strategic R&D partner, SciCann Therapeutics Inc. received a positive International Search Authority (ISA) report from the Patent Cooperation Treaty for its SCN-001 cannabidiol combination therapy, the basis of its “Steady Stomach” product.

 

The comprehensive prior art search performed by ISA for the PCT/IL2018/051000 patent application by SciCann led the agency to conclude that the enhanced CBD combination therapy claimed by the patent application is novel and inventive.

 

Under the terms of FSD’s strategic agreement with SciCann, FSD holds exclusive manufacturing and distribution rights for the “Steady Stomach” product in Canada.

 

Dr. Zohar Koren, Co-founder and CEO of SciCann stated, “This patent application covers the “Steady Stomach” product, for which we have recently launched the company’s first clinical study with Irritable Bowel Syndrome (IBS) patients. The preliminary affirmation we received from the ISA regarding the novelty of this unique combination therapy is an important milestone, which allows us to file national phase applications in the US, Canada and the rest of the world in order to achieve comprehensive IP protection for the product. We believe that our strategy of developing novel and proprietary synergistic combination cannabinoid therapies is the right approach to bring new and IP protected products to the cannabinoid based pharmaceutical space.”

 

Dr. Raza Bokhari, CEO of FSD Pharma stated, “This positive ISA report for CBD combination therapy is welcome news for FSD Pharma. We expect SciCann’s Steady Stomach product, currently in the phase I/II clinical development stage, to have a positive impact in the lives of IBS patients. FSD’s exclusive distribution rights for the product in Canada is in line with our company’s continuing efforts in research and development of novel and proprietary, cannabinoid-based treatments.”

 

About FSD Pharma

 

FSD Pharma is focused on the development of the highest quality indoor grown, pharmaceutical grade cannabis and on the research and development of novel cannabinoid-based treatments for several central nervous system disorders, including chronic pain, fibromyalgia and irritable bowel syndrome. The Company’s phase one growth plan involves the development of 25,000 square feet of indoor grow space at its Ontario facility and an additional 220,000 square feet, which pending approval by Health Canada, is expected to be operational in the first quarter 2019.

 

FSD facilities sit on 72 acres of land with 40 acres primed for development and an expansion capability of up to 3,896,000 square feet.

 

FSD’s wholly-owned subsidiary, FV Pharma, is a licensed producer of cannabis having received its cultivation license under the Access to Cannabis for Medical Purposes Regulations (ACMPR) on October 13, 2017 and is now operating under the recently enacted Cannabis Act. FV Pharma vision is to transform its current headquarters in a Kraft plant in Cobourg, Ontario into the largest hydroponic indoor grow facility in the world. FV Pharma intends to cover all aspects of this exciting, new industry, including cultivation, legal, processing, manufacturing, extracts and research and development.

 

About SciCann Therapeutics

 

SciCann Therapeutics is a Canadian-Israeli specialty pharmaceutical company, dedicated to the development and commercialization of novel and disruptive pharmaceutical products that target and modulate the endocannabinoid system. SciCann Therapeutics is active in the fields of oncology, pain management, neurodegenerative diseases and inflammatory disorders, and develops a line of proprietary products for the treatment of life-threatening conditions that present a high level of unmet need.

 

SciCann has created a network of collaborations with leading academic centers and medical institutions in Israel to engage in cutting edge science and rigorous clinical studies to develop its products, while using the permissive regulatory climate in Israel for performing its R&D programs quickly and efficiently.

 

Posted November 6, 2018

Share this news article...
Share on LinkedIn
Linkedin
Share on Facebook
Facebook
Tweet about this on Twitter
Twitter
Share on Google+
Google+
Email this to someone
email

MORE or "UNCATEGORIZED"


Shopbrain Launches AI-Powered Shopping Assistant in the U.S. & Canada Ahead of Holiday Season

Shopbrain today announces the launch of its latest product –... READ MORE

November 14, 2018

Mobeewave Closes US$16.5M Series B Round led by NewAlpha, Mastercard and Forestay Capital

Mobeewave, pioneers in in-person contactless payment acceptance, ... READ MORE

November 14, 2018

Muskoka Grown Secures $10,000,000 in Financing, Accelerating Expansion Plans

Muskoka Grown Limited, a small-batch premium craft cannabis produ... READ MORE

November 14, 2018

Seraphim Solar Secures 80 MW Supply Agreement in Vietnam

Jiangsu Seraphim Solar System Co., Ltd. recently signed new landm... READ MORE

November 13, 2018

FSD Pharma Receives License to Sell to Other Licensed Producers and Expands Growth Production Footprint

FSD Pharma Inc. (CSE: HUGE) (OTCQB: FSDDF) (FRA: 0K9) announced t... READ MORE

November 13, 2018

Copyright 2018 The Venture Report